Estados Unidos · Bolsa y Finanzas · Morningstar

'Pharma Bro' Martin Shkreli is in trouble with regulators again, this time for influencing biopharma stocks

Publicado por Morningstar · Estados Unidos hace 9 h

The Federal Trade Commission and seven states say Shkreli should be held in contempt Martin Shkreli was found guilty in 2017 of two counts of securities fraud and one count of…

Leer el artículo completo en Morningstar Inicie sesión para guardar

MediaNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.morningstar.com)

'Pharma Bro' Martin Shkreli is in trouble with regulators again, this time for influencing biopharma stocks

También te puede interesar

Police Identify 42-Year Old Man Killed at Six Flags Over Georgia

Google opens Gemini 4 Argon AI model to developers and businesses worldwide

The best Airbnb long-term rentals in 2026 — Marrakesh to Panama

Dangote Swings to $4.7 Billion Profit Ahead of Africa’s Biggest IPO

Satlyt, founded by a former Google and SpaceX product manager, raises $8M to run AI on satellites

Trezor Cuts Its Resellers After Ledger Finds Spy Implant in Crypto Wallets

'Pharma Bro' Martin Shkreli is in trouble with regulators again, this time for influencing biopharma stocks

Compartir

También te puede interesar

Police Identify 42-Year Old Man Killed at Six Flags Over Georgia

Google opens Gemini 4 Argon AI model to developers and businesses worldwide

The best Airbnb long-term rentals in 2026 — Marrakesh to Panama

Dangote Swings to $4.7 Billion Profit Ahead of Africa’s Biggest IPO

Satlyt, founded by a former Google and SpaceX product manager, raises $8M to run AI on satellites

Trezor Cuts Its Resellers After Ledger Finds Spy Implant in Crypto Wallets